ITOS stock forecast
Our latest prediction for ITeos Therapeutics Inc's stock price was made on the Sept. 22, 2021 when the stock price was at 27.46$.
In the short term (2weeks), ITOS's stock price should underperform the market by -2.45%. During that period the price should oscillate between -10.28% and +9.13%.
In the medium term (3months), ITOS's stock price should underperform the market by -0.90%. During that period the price should oscillate between -34.06% and +31.32%.Get email alerts
Create a solid portfolio with ITOS
About ITeos Therapeutics Inc
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of cancer immunology and immunosuppressive pathways to design novel product candidates with the potential to fully restore the immune response against cancer. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes. The initial antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism. An open-label Phase 1/2a clinical trial of EOS-448 is ongoing in adult cancer patients with advanced solid tumors with preliminary data indicating clinical activity as a monotherapy and a favorable tolerability profile. The Company is also advancing inupadenant, a next-generation adenosine A2A receptor antagonist tailored to overcome cancer immunosuppression. iTeos is conducting an open-label multi-arm Phase 1/2a clinical trial of inupadenant in adult cancer patients with advanced solid tumors. Preliminary results indicate encouraging single-agent activity in the dose escalation portion of the trial. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -3.49$ per share.
The book value per share is 9.21$
Three months stock forecastSept. 22, 2021
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|